Crown Labs buys 5 brands from GSK
Johnson City, Tenn.-based Crown Labs has added several OTC brands to its portfolio. The company purchased the North American distribution rights for acne wash PanOxyl, anti-itch lotion Sarna, antifungal Zeasorb, antifungal powder Desenex and pain-relief gel Mineral Ice from GlaxoSmithKline.
“Acquiring these strong heritage brands strengthens Crown’s OTC portfolio and adds significant value across multiple categories,” said Jeff Bedard, Crown Labs president and CEO. “I am especially excited to bring the Stiefel brands to Crown as I personally enjoyed tremendous success in marketing them as a field sales representative for Stiefel in the ’80s and ’90s.”
Crown Labs, a Hildred Capital Partners Portfolio company, and partner David Solomon, who also is chairman of Crown Labs, said, “The addition of these brands provides meaningful diversification for our OTC portfolio and enhances our breadth of trusted consumer skin care therapies. We will continue to look for interesting opportunities to build on Crown’s consumer healthcare, aesthetic and prescription product lines.”
Crown Labs has selected the Emerson group to manage the sales activity and logistics of the products.
“We are extremely excited to partner with Crown Laboratories,” said Scott Emerson, chairman and CEO of the Emerson Group. “Crown’s management team, dermatology expertise and enhanced resources will serve the acquired brands well in a very attractive growth category for our retailers.”
“Acquiring these strong heritage brands strengthens Crown’s OTC portfolio and adds significant value across multiple categories,” said Jeff Bedard, Crown Labs president and CEO. “I am especially excited to bring the Stiefel brands to Crown as I personally enjoyed tremendous success in marketing them as a field sales representative for Stiefel in the ’80s and ’90s.”
Crown Labs, a Hildred Capital Partners Portfolio company, and partner David Solomon, who also is chairman of Crown Labs, said, “The addition of these brands provides meaningful diversification for our OTC portfolio and enhances our breadth of trusted consumer skin care therapies. We will continue to look for interesting opportunities to build on Crown’s consumer healthcare, aesthetic and prescription product lines.”
Crown Labs has selected the Emerson group to manage the sales activity and logistics of the products.
“We are extremely excited to partner with Crown Laboratories,” said Scott Emerson, chairman and CEO of the Emerson Group. “Crown’s management team, dermatology expertise and enhanced resources will serve the acquired brands well in a very attractive growth category for our retailers.”